breast cancer

Atossa Therapeutics reported Q1 2026 expenses of $9.9M, secured FDA orphan drug designation for lead candidate (Z)-endoxifen in rare diseases.

IceCure Medical showcased ProSense® cryoablation at breast surgeons conference, reporting 30%+ Q1 revenue growth as adoption accelerates.

Arvinas wins landmark FDA approval for VEPPANU, first PROTAC protein degrader for breast cancer, ahead of schedule. Reports Q1 2026 results May 12.

FDA approves VEPPANU, first PROTAC therapy for advanced breast cancer with ESR1 mutations, showing 43% reduction in disease progression risk versus existing treatment.

Arvinas and Pfizer secure FDA approval for VEPPANU, the first PROTAC protein degrader, for ESR1-mutated breast cancer based on Phase 3 data showing 43% progression-risk reduction.

AstraZeneca's prostate drug Truqap wins FDA panel backing (7-1 vote) for PTEN-deficient tumors, but breast cancer candidate camizestrant rejected despite superior efficacy data.

Beyond Cancer presented Phase 1 UNO trial data with six of ten patients alive 22-40 months post-treatment and secured U.S. patent for gas delivery technology.

Greenwich LifeSciences reports significant immune response gains in Phase III FLAMINGO-01 trial for GLSI-100 breast cancer recurrence prevention, showing 70-80% recurrence reduction.

Boundless Bio presented preclinical data for BBI-940, an oral kinesin degrader targeting extrachromosomal DNA in breast cancer, with Phase 1 trials underway.

Incyclix Bio raises $5M from Hatteras Venture Partners for Phase 1/2 trial of INX-315, targeting therapy-resistant breast and ovarian cancers.

Merit Medical Systems acquires View Point Medical for $140M, adding breast cancer imaging technology. Expected to dilute 2026 earnings but turn accretive in 2027.

Natera's MRD test shows older breast cancer patients may avoid surgery. Study demonstrates perfect detection rates, boosting NTRA stock 5.26% to $196.68.

Celcuity stock rises over 4% after beating loss expectations and securing $166M cash position, with phase 3 trial results anticipated in Q2.

IceCure Medical ($ICCM) names Meir Peleg as CFO and appoints Dr. Richard Fine as Medical Director, capitalizing on ProSense® cryoablation system's FDA clearance momentum.

Novartis acquires SNV4818, a next-gen PI3Kα inhibitor, from Synnovation for $2B upfront plus $1B milestones to treat PIK3CA-mutated breast cancer.

Pfizer shares rise on Phase 3 prostate cancer trial win and Phase 2 breast cancer success, validating its oncology pipeline and signaling near-term regulatory catalysts.

Greenwich LifeSciences expands FLAMINGO-01 trial with City of Hope, growing sites to 190-200. Preliminary data shows 70-80% recurrence reduction in breast cancer immunotherapy study.

$GLSI's GLSI-100 immunotherapy demonstrates 70-80% recurrence reduction in Phase III trial data accepted for AACR presentation.

Pfizer reports positive Phase 2 data for atirmociclib in metastatic breast cancer, meeting survival endpoints. Company also gains FDA approval for Braftovi in colorectal cancer.

ASBrS endorses cryoablation for low-risk breast cancer, validating IceCure Medical's ProSense system cleared by FDA in October 2025.